GlassScriptPhysician profile
Pamela I Smith
NPI 1114221785
$5,062.28
in general payments reported to CMS, 2019-2025
30 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $531 · 2023: $1,274 · 2024: $1,568 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,406.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $638.70 | 2021-2025 | Rybelsus, Wegovy, Ozempic |
| Smith+Nephew, INC. | $566.33 | 2023-2025 | Collagenase Santyl, Grafix, Oasis |
| Lilly USA, LLC | $545.81 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Organogenesis INC. | $311.34 | 2023-2024 | Puraply Wound Matrix, Puraply, Puraply Am |
| Coloplast Corp | $263.35 | 2023-2024 | Sensura Mio |
| Glaxosmithkline, LLC. | $263.01 | 2023-2024 | Arexvy, Shingrix |
| Abbvie INC. | $206.39 | 2023-2024 | |
| Vertex Pharmaceuticals Incorporated | $185.85 | 2025 | |
| Madrigal Pharmaceuticals | $135.31 | 2025 | Rezdiffra |
| Recordati_rare_diseases_inc. | $132.89 | 2025 | Isturisa |
| Convatec INC. | $129.49 | 2024 | |
| Amgen INC. | $125.04 | 2024 | Evenity |
| Corcept Therapeutics | $125.00 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $124.98 | 2024 | Farxiga |
| Dexcom, INC. | $124.06 | 2023 | Dexcom G7 Gss (161) |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $111.16 | 2024 | |
| Urgo Medical North America, LLC | $110.75 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Abbott Laboratories | $101.37 | 2023 | Freestyle Libre 3 |
| Avita Medical Americas, LLC | $100.87 | 2025 | Recell |
| Si-Bone, INC. | $100.63 | 2022 | |
| Kci USA, INC. | $82.40 | 2023 | V.A.C. Dermatac, Promogran Prisma, V.A.C. Veraflo |
| Pfizer INC. | $81.81 | 2024 | |
| Hollister Incorporated | $78.82 | 2025 | New Image, Premier |
| Medline Industries LP | $76.11 | 2023 | |
| Aurinia Pharma U.S., INC. | $71.98 | 2024 | Lupkynis |
| Phadia US INC. | $68.75 | 2022 | |
| W. L. Gore & Associates, INC. | $61.66 | 2023 | Gore Excluder Aaa Endoprosthesis |
| Biosense Webster, INC. | $59.36 | 2022 | |
| Angiodynamics, INC. | $58.23 | 2025 | Auryon Laser System 100-120 Vac |
| Exact Sciences Corporation | $20.83 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.